NCT03144661终止1 期
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 25
- 试验地点
- 6
- 主要终点
- Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs)
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Part 1: HCC; cholangiocarcinoma; or esophageal, nasopharyngeal, or serious ovarian cancer, regardless of FGF19/FGFR4 status; or other solid tumor malignancies with documented FGF19/FGFR4 alteration (FGF19/FGFR4 pathway activating alterations include, but are not limited to, FGFR4 amplification, FGFR4 activating mutations, and FGF19 amplification) based on local testing.
- •Part 2: Subjects will be enrolled into 1 of 3 cohorts:
- •Cohort A: HCC with FGF19 amplification.
- •Cohort B: HCC without FGF19 amplification.
- •Cohort C: cholangiocarcinoma, esophageal, nasopharyngeal or serous ovarian cancers (regardless of FGF19/FGFR4 status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.
- •Has progressed after prior therapy and either a) there is no further effective standard anticancer therapy available (including subject refusal) or b) is intolerant to standard anticancer therapy.
- •Life expectancy > 12 weeks.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Part 1) or 0-2 (Part 2).
- •Archival tumor specimen according to protocol-defined criteria.
- •Centrally analyzed screening C4 (bile acid synthesis precursor) results must be below 40.9 ng/mL, which is the upper limit as determined by the sponsor.
- •Must agree to take bile acid sequestrants while taking INCB062079.
排除标准
- •Treatment with other investigational study drug for any indication for any reason, or receipt of anticancer medications within 28 days before first dose of study drug; subjects must have recovered from AEs due to previously administered therapies.
- •Prior receipt of a selective FGFR4 inhibitor within the last 6 months.
- •Laboratory parameters outside the protocol-defined ranges.
- •History or presence of an abnormal ECG that in the investigator's opinion is clinically meaningful.
- •Prior radiotherapy within 2 weeks of study treatment. A 1-week washout period is permitted for palliative radiation to non- central nervous system (CNS) disease with medical monitor approval.
- •History of human immunodeficiency virus infection.
- •Untreated brain or CNS metastases or brain/CNS metastases that have progressed. Subjects with previously treated and clinically stable brain/CNS metastases and who are off all corticosteroids for ≥ 4 weeks are eligible.
- •Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment, except concomitant antiviral systemic therapy for chronic hepatitis B or C.
- •Child-Pugh liver function Class B or C.
- •History of clinically significant or uncontrolled cardiac disease.
- •History of allergic reactions to INCB062079, any of the excipients of INCB062079 or similar compounds.
- •Pregnant or nursing women or subjects expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 90 days after last dose of study drug.
- •Any medical condition that would in the investigator's judgment interfere with full participation in the study, including administration of study medication and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.
研究组 & 干预措施
Part 1 - INCB062079 10mg QD
Experimental
INCB062079 was administered at 10mg once daily
干预措施: INCB062079 (Drug)
Part 1 - INCB062079 10mg BID
Experimental
NCB062079 was administered at 10mg twice daily
干预措施: INCB062079 (Drug)
Part 1 - INCB062079 15mg BID
Experimental
NCB062079 was administered at 15mg twice daily
干预措施: INCB062079 (Drug)
Part 1 - INCB062079 10 mg BID + BAS
Experimental
NCB062079 was administered at 10 mg twice daily in combination with bile acid sequestrants (BAS)
干预措施: INCB062079 (Drug)
Part 1 - INCB062079 15 mg BID + BAS
Experimental
NCB062079 was administered at 15mg twice daily in combination with bile acid sequestrants (BAS)
干预措施: INCB062079 (Drug)
Part 2 Dose Expansion - Cohort A
Experimental
HCC Subjects with FGF19 amplification were enrolled to evaluate the dose selected in Part 1
干预措施: INCB062079 (Drug)
Part 2 - Dose Expansion Cohort B
Experimental
HCC Subjects without FGF19 amplification were enrolled to evaluate the dose selected in Part 1
干预措施: INCB062079 (Drug)
Part 2 - Dose Expansion Cohort C
Experimental
Subjects with cholangiocarcinoma or esophageal, nasopharyngeal, or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration were enrolled to evaluate the dose selected in Part 1
干预措施: INCB062079 (Drug)
结局指标
主要结局
Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs)
时间窗: Baseline to 30-35 days after end of treatment, up to approximately 6 months per subject.
An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a subject provides informed consent.
次要结局
- Cmax of INCB062079(Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject.)
- Tmax of INCB062079(Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject.)
- Objective Response Rate(Every 2 cycles during the treatment period and every 8 weeks during the follow-up period, up to approximately 6 months per subject.)
- Cmin of INCB062079(Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject.)
- AUC0-t of INCB062079(Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject.)
- t½ of INCB062079(Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject.)
- Cl/F of INCB062079(Protocol-defined time points during Cycles 1 and 2 of treatment, up to approximately 2 months per subject.)
- Analysis of biomarkers(Screening visit)
研究者
研究点 (6)
Loading locations...
相似试验
招募中
1 期
Study of SGR-1505 in Mature B-Cell NeoplasmsMature B-Cell NeoplasmNon Hodgkin LymphomaWaldenstrom MacroglobulinemiaMALT LymphomaPediatric-Type Follicular LymphomaFollicular LymphomaDLBCLIRF4 Gene RearrangementEBV-Positive DLBCL, NosBurkitt LymphomaPlasmablastic LymphomaHigh-grade B-cell LymphomaDLBCL Germinal Center B-Cell TypePrimary Mediastinal Large B Cell LymphomaT-Cell/Histiocyte Rich LymphomaALK-Positive Large B-Cell LymphomaPrimary Cutaneous Diffuse Large B-Cell LymphomaSplenic Marginal Zone LymphomaNodal Marginal Zone LymphomaHHV8-Positive DLBCL, NosLymphoplasmacytic LymphomaDuodenal-Type Follicular LymphomaChronic Lymphocytic LeukemiaMantle Cell LymphomaPrimary Cutaneous Follicle Center LymphomaPrimary Effusion LymphomaNCT05544019Schrödinger, Inc.98
已完成
1 期
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple MyelomaMultiple MyelomaNCT00963820Millennium Pharmaceuticals, Inc.60
已完成
1 期
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).Acute Myeloid LeukemiaNCT03298984Sumitomo Pharma America, Inc.32
进行中（未招募）
1 期
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell MalignanciesMature B-Cell MalignanciesNCT04277637BeOne Medicines437
终止
1 期
Dose Escalation of IPI-493 in Hematologic MalignanciesHematologic MalignanciesNCT01193491Infinity Pharmaceuticals, Inc.4